Product Name: HIPK1 (349-355) pY352
Product Number: PE-04AKK95
Size: | 200 µg | | Price: | 47.00 |
| 1 mg | | $US | 94.00 |
| 5 mg | | | 206.00 |
Peptide Name: HIPK1 (349-355) pY352
Product Use: Services as a blocking peptide for use with the HIPK1-pY352 rabbit polyclonal antibody (Cat. No.: AB-PK654) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. This is the major in vivo phosphorylation site in HIPK1. Y352 phosphorylation is predicted to be stimulatory for phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CST-pY-LQS
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1022 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: HIPK1 - pY352 phosphosite-specific antibody (Cat. No.: AB-PK654) Scientific Background: HIPK1 (HIK1) is a protein-serine/threonine kinase of the CMGC group and DYRK family. It functions in transcription regulation as well as tumour necrosis factor (TNF)-mediated apoptosis. HIPK1 is also known to act as a co-repressor for homeodomain transcription factors. In the absence of TNF, HIPK1 prevents MAP3K5-JNK activation. When present, TNF induces nuclear translocation of HIPK1, thus removing it from the cytoplasm, resulting in the activation of MAP3K5-JNK signalling by de-repression. In addition, through the direct phosphorylation of p53 at the S15 residue, HIPK1 activates p53 leading to increased p21 protein levels, which subsequently inhibits cell proliferation. HIPK1 may be a tumour suppressor protein (TSP). Over-expression of HIPK1 has been observed in colorectal cancer specimens, with highest levels at the beginning of tumourigenesis followed by a progressive reduction over time as the cancer develops, indicating a role for the HIPK1 protein in the early events of tumourigenesis. in addition, these specimens also displayed native p53 and normal levels of p21, indicating that the HIPK1 protein functions as a tumour suppressor and that a loss-of-function in the protein is associated with tumourigenesis.